Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
Vestre Viken Hosp Trust, Baerum Hosp, Dept Med, Drammen, Norway.;Univ Oslo, Inst Clin Med, Oslo, Norway..
Gentofte Univ Hosp, Dept Gastroenterol, Hellerup, Denmark..
Sodra Alvsborg Hosp, Dept Internal Med, Boras, Sweden..
Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Aalborg, Denmark..
Show others and affiliations
2017 (English)In: Gastroenterology Research and Practice, ISSN 1687-6121, E-ISSN 1687-630X, Vol. 2017, article id 4585164Article in journal (Refereed) Published
Abstract [en]

Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside. Methods. A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction.

Place, publisher, year, edition, pages
2017. Vol. 2017, article id 4585164
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-340115DOI: 10.1155/2017/4585164ISI: 000413310800001OAI: oai:DiVA.org:uu-340115DiVA: diva2:1178880
Available from: 2018-01-31 Created: 2018-01-31 Last updated: 2018-01-31Bibliographically approved

Open Access in DiVA

fulltext(1455 kB)1 downloads
File information
File name FULLTEXT01.pdfFile size 1455 kBChecksum SHA-512
502deebe5662706b01842ca7ce0d3e729a1bfa63126c73b586002c05a764ea3eeaaba848f331760b1af9d3e8b62f6a7fd90c2826792e9f9214f5a6e77c78f3ce
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Hellström, Per M.
By organisation
Gastroenterology/Hepatology
In the same journal
Gastroenterology Research and Practice
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar
Total: 1 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf